| 4 | Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations显示文摘The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer’s or Parkinson’s disease. These may not be sufficiently valid or sensitive to treatment changes in DLB, decreasing their utility. In this review, we discuss the limitations and strengths of selected available tools used to measure DLB-associated outcomes in clinical trials and highlight the potential roles for more specific objective measures. We emphasize that the existing outcome measures require validation in the DLB population and that DLB-specific outcomes need to be developed. Finally, we highlight how the selection of outcome measures may vary between symptomatic and disease-modifying therapy trials. | Federico Rodriguez-Porcel Kathryn A.Wyman-Chick Carla Abdelnour Ruiz Jon B.Toledo Daniel Ferreira Prabitha Urwyler Rimona S.Weil Joseph Kane Andrea Pilotto Arvid Rongve Bradley Boeve John-Paul Taylor Ian McKeith Dag Aarsland Simon J.G.Lewis the Lewy Body Dementias Clinical Trials Workgroup from the Lewy Body Dementias Professional Interest Area-Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment(ISTAART) | 2022 | Translational Neurodegeneration2022，11，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员